22 results about "Cycloserine" patented technology

The present invention relates to a pesticidal composition comprising a component A and a component B, characterized in that the component A is isocycloseram, and the component B is a component selected from Bacillus species, its fermentation solids, and its insecticidal toxins.

The present invention relates to a method for preparing a substituted cycloserine compound of formula (I) wherein R 1 is C1-C8 alkyl, C1-C8 haloalkyl, C3-C6 cycloalkyl, aryl or aryl substituted with one to five R 11 substituents, or aryl-C1-C4 alkylene or aryl-C1-C4 alkylene substituted with one to five R 11 substituents; and each R 11 is independently C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, cyano or halogen; the present invention also relates to intermediates produced by these methods. Compounds of formula (I) are useful intermediates for the production of compounds in the agricultural and pharmaceutical fields.

This application relates to combination compositions for use in treatment of depression, and which can alleviate the anxiogenic side effects of certain antidepressant and antipsychotic medications. Methods for treatment of depression and medicament side effects, particular anxiety, akathisia, and associated suicidality are also described herein.

The present invention provides a therapeutic or prophylactic agent for amyotrophic lateral sclerosis resulting from aggregation of TDP-43 in nerve cells, the therapeutic or prophylactic agent for amyotrophic lateral sclerosis containing an active ingredient at an amount greater than 100 mg and less than 250 mg, the active ingredient essentially being composed of at least one selected from the group consisting of cycloserine, terizidone, and salts thereof. The active ingredient may be composed of at least one selected from the group consisting of cycloserine, terizidone, and salts thereof. The cycloserine may be D-cycloserine. The cycloserine may be L-cycloserine.

The present invention relates to a composition comprising: (a) isocycloseram, (b) emamectin, and (c) a sulfonated lignin compound having a molecular weight up to 10,000 g / mol.

The present invention belongs to the field of pharmaceuticals. Disclosed in the present invention are a class of salt compounds of isosorbide mononitrate derivatives and the use thereof. Salts formed by the isosorbide mononitrate derivatives of the present invention and D-cycloserine exhibit dual activities as a nitric oxide donor and a partial NMDA receptor agonist. The present invention further relates to the use of the salts formed by the isosorbide mononitrate derivatives and D-cycloserine in a drug for treating cerebral stroke or the recovery period of cerebral stroke.

1. Name of the product in this design: Packaging Box (Cycloserine Capsules). 2. Intended use of this design: This design is intended for the packaging, storage, and transportation of pharmaceuticals. 3. Key design features of this design: The key design features of this design are the combination of the product's shape and pattern. 4. The image or photograph that best illustrates the design's key points: a 3D model. 5. The design for which protection is sought includes color.

This invention relates to a composition comprising: (a) isocycloseram, and (b) a lignin compound having an average molecular weight up to 10000 g / mol.

The invention relates to the technical field of drug detection, and particularly discloses a method for detecting related substances in cycloserine. The specific derivatization reagent is adopted, so that the impurities and the benzaldehyde derivative are subjected to derivatization reaction to generate amide, and the ultraviolet absorption response intensity of the impurities is improved; according to the method, a ZORBAX SB-Phenyl chromatographic column is adopted to carry out HPLC (High Performance Liquid Chromatography) analysis on a cycloserine sample, so that rapid and accurate detection on impurities such as D-serine, D-serine methyl ester hydrochloride, 3-chloro-D-alanine methyl ester hydrochloride and L-cycloserine in the cycloserine at the same time is realized. The detection method is high in specificity, low in detection limit and quantitation limit, good in linear relation, high in recovery rate, good in repeatability, high in stability, good in durability, easy and rapid to operate, low in detection cost and accurate and reliable in detection result, can be used for quality control and comprehensive evaluation of cycloserine, and provides reliable guarantee for improving and controlling the quality of cycloserine.

An inhibitor of aggregation of TDP-43 comprising a combination of at least one compound selected from the group consisting of cycloserine and terizidone and their salts, and edaravone. An inhibitor of the aggregation of TDP-43, which contains at least one compound selected from the group consisting of cycloserine and terizidone, and salts thereof, in combination with edaravone. An inhibitor of aggregation of TDP-43 comprising edaravone in combination with at least one compound selected from the group consisting of cycloserine and terizidone and their salts.

The present invention relates to a combination therapy of cycloserine and lithium for the prevention or treatment of depression. The combined administration of cycloserine and lithium according to the present invention has a remarkably excellent effect of preventing or treating depression compared to each single administration, thereby being effectively utilized as a combination therapy for antidepressants.

This invention relates to a method (I) for preparing substituted cyclic serine compounds having the chemical formula (I), wherein R 1 It is a C1-C8 alkyl, C1-C8 haloalkyl, C3-C6 cycloalkyl, aryl, or surrounded by one to five Rs. 11 Substituted aryl, or aryl-C1-C4 alkylene, or with one to five R 11 Substituted aryl-C1-C4 alkylene groups; and each R 11 The compounds are independently C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, cyano, or halogen; the invention also relates to intermediates produced by these methods. Compounds having chemical formula (I) are useful intermediates for the production of compounds in the agricultural and pharmaceutical fields.

The invention discloses a pharmaceutical composition containing cycloserine or a stereoisomer of the cycloserine or a pharmaceutically acceptable salt of the cycloserine and lysine modified amino tetraphenyl porphyrin or a stereoisomer of the lysine modified amino tetraphenyl porphyrin or a pharmaceutically acceptable salt of the lysine modified amino tetraphenyl porphyrin. The preparation method comprises the following steps: mixing cycloserine or a stereoisomer of the cycloserine or a pharmaceutically acceptable salt of the cycloserine and lysine-modified amino tetraphenyl porphyrin or a stereoisomer of the lysine-modified amino tetraphenyl porphyrin or a pharmaceutically acceptable salt of the lysine-modified amino tetraphenyl porphyrin according to a mass ratio of 512: 1-1: 2000; or a pharmaceutically acceptable carrier is added to prepare a clinically acceptable dosage form. The invention further provides application of the pharmaceutical composition in preparation of bacterial infection resisting drugs and tissue repair promoting drugs. The pharmaceutical composition disclosed by the invention has a synergistic antibacterial effect and is good in biocompatibility.

The invention provides a method for inhibiting aspergillus flavus by using D-cycloserine, relates to the technical field of fungus biological control, and provides application of D-cycloserine in inhibition of aspergillus flavus, including inhibition of growth of aspergillus flavus and inhibition of spore number of aspergillus flavus. Solid and liquid culture systems prove that the D-cycloserine can significantly inhibit aspergillus flavus mycelium expansion, spore formation and mycelium pellet development, and dose-dependently reduce the biosynthesis of aflatoxins B1, B2, G1 and G2. The invention reports that the D-cycloserine has the capability of inhibiting aspergillus flavus and aflatoxin for the first time, and provides new selectivity for prevention and control of aspergillus flavus.

A therapeutic or prophylactic agent for frontotemporal lobe degeneration accompanying TDP-43 accumulation, i.e., FTLD-TDP, the active ingredient of which essentially comprises at least one compound selected from the group consisting of cycloserine, terizidone, and salts thereof.

The present invention relates to a pesticidal composition comprising a active ingredient A and a active ingredient B, characterized in that the active ingredient A is isocycloseram, and the active ingredient B is selected from C16-C18-alkylcarboxylic acids, C16-C18-alkylcarboxylic acid salts, and any combination thereof.

The invention discloses a novel cycloserine intermediate compound and a novel process route for preparing a cycloserine derivative. The compound is simple and convenient to synthesize and easy to control, when the intermediate compound is used for preparing the cycloserine derivative, the process route is simple and convenient, the reaction condition is mild, the operation process is simple and convenient, the production cost is low, and the prepared cycloserine derivative has relatively high purity and high yield.

The present invention relates to a composition comprising an active ingredient A and an active ingredient B, characterized in that the active ingredient A is isocycloseram, and the active ingredient B is acibenzolar-s-methyl.

The present inventions concerns use of isocycloseram to control mosquitoes including mosquito vectors of pathogenic disease and mosquitoes having developed insecticide resistance, such as pyrethroid insecticide resistance.

The present invention relates to a composition comprising: (a) isocycloseram, (b) emamectin, and (c) a sulfonated lignin compound having a molecular weight up to 10,000 g / mol.

The invention discloses a preparation method of D-cycloserine. The preparation method comprises the step of drying a D-cycloserine crystal form III to obtain anhydrous D-cycloserine. The preparation method disclosed by the invention is simple and convenient to operate, and the obtained D-cycloserine is large in granularity and good in product fluidity.

The present invention relates to a composition comprising components (A) and (B) as active ingredients, wherein component (A) comprises a Streptomyces chrestomyceticus and component (B) is a compound selected from the group consisting of prothioconazole, difenoconazole, mefentrifluconazole, hexaconazole, propiconazole, bromuconazole, fenpropidin, spiroxamine, isoprothiolane, pydiflumetofen, benzovindiflupyr, isoflucypram, isopyrazam, fluxapyroxad, cyprodinil, azoxystrobin, pyraclostrobin, metyltetraprole, proquinazid, tricyclazole, florylpicoxamid, fenpicoxamid, N-(2,4-dimethyl-1-phenylpentan-2- yl)-8-fluoroquinoline-3-carboxamide, ipflufenoquin, quinofumelin, zinc thiazole, folpet, chlorothalonil, acibenzolar-S-methyl, fosetyl- aluminium, oxolinic acid, anisiflupurin, inpyrfluxam, metalaxyl, metalaxyl-M, triticonazole, penthiopyrad, sedaxane, thiabendazole, imidacloprid, thiamethoxam, fludioxonil, fluoxastrobin, silthiofam, chlorantraniliprole, ethaboxam, ipconazole, cyantraniliprole, oxathiapiprolin, fluopyram, picarbutrazox, cyclobutrifluram, isocycloseram, and fluoxapiprolin. The invention further relates to a method of controlling or preventing phytopathogenic diseases, preferably phytopathogenic fungi, on a plant or on plant propagation material and / or on harvested food crops, which comprises applying to the plant, on plant propagation material, the locus thereof, and / or on harvested food crops the composition according to the present invention.